{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:48:06Z","timestamp":1789051686444,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01483-2","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:39:15Z","timestamp":1754584755000},"page":"3037-3053","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-8193","authenticated-orcid":false,"given":"Lauren C. S.","family":"Kole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Chen-Yin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ren\u00e9e","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhal","family":"K\u00fc\u00e7\u00fckosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"4","key":"1483_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.18851","volume":"37","author":"L Puig","year":"2023","unstructured":"Puig L, Choon SE, Gottlieb AB, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023;37(4):737\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1483_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s13555-022-00881-0","volume":"13","author":"R Rivera-D\u00edaz","year":"2023","unstructured":"Rivera-D\u00edaz R, Daud\u00e9n E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther (Heidelb). 2023;13(3):673\u201388.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1483_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1483_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","volume":"11","author":"B Strober","year":"2021","unstructured":"Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1483_CR5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/exd.14787","volume":"32","author":"PM Patel","year":"2023","unstructured":"Patel PM, Sanchez-Melendez SN, Nambudiri VE. A narrative review of studies assessing the quality of life in patients with generalized pustular psoriasis. Exp Dermatol. 2023;32(8):1227\u201334.","journal-title":"Exp Dermatol"},{"issue":"Suppl 1","key":"1483_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40257-021-00663-y","volume":"23","author":"DV Reisner","year":"2022","unstructured":"Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(Suppl 1):65\u201371.","journal-title":"Am J Clin Dermatol"},{"issue":"10412","key":"1483_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","volume":"402","author":"A Morita","year":"2023","unstructured":"Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541\u201351.","journal-title":"Lancet"},{"key":"1483_CR8","doi-asserted-by":"crossref","unstructured":"Augustin M, Gottlieb AB, Tada Y, et al. Generalized pustular psoriasis (GPP) continues to adversely impact quality of life between flares, as per Dermatology Life Quality Index scores: baseline data from the Effisayil 2 trial. Poster 51782. Presented at: American Academy of Dermatology (AAD) Annual Meeting, 8\u201312 March 2024, San Diego","DOI":"10.1016\/j.jaad.2024.07.873"},{"issue":"6","key":"1483_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s13555-022-00736-8","volume":"12","author":"AD Burden","year":"2022","unstructured":"Burden AD, Mrowietz U, Skalicky AM, et al. Symptom experience and content validity of the psoriasis symptom scale (PSS) in patients with generalized pustular psoriasis (GPP). Dermatol Ther (Heidelb). 2022;12(6):1367\u201381.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1483_CR10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1346-8138.16022","volume":"48","author":"A Morita","year":"2021","unstructured":"Morita A, Kotowsky N, Gao R, Shimizu R, Okubo Y. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database. J Dermatol. 2021;48(10):1463\u201373.","journal-title":"J Dermatol"},{"issue":"2","key":"1483_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jdv.19530","volume":"38","author":"SE Choon","year":"2024","unstructured":"Choon SE, De La Cruz C, Wolf P, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2024;38(2):265\u201380.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1483_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13555-024-01103-5","volume":"14","author":"T Bhutani","year":"2024","unstructured":"Bhutani T, Farberg AS. Clinical and disease burden of patients with generalized pustular psoriasis: a review of real-world evidence. Dermatol Ther (Heidelb). 2024;14(2):341\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 1","key":"1483_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"J Krueger","year":"2022","unstructured":"Krueger J, Puig L, Tha\u00e7i D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51\u201364.","journal-title":"Am J Clin Dermatol"},{"key":"1483_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/24755303251318976","author":"B Elewski","year":"2025","unstructured":"Elewski B, Lebwohl MG. Management of chronic generalized pustular psoriasis: a review and expert opinion. J Psoriasis Psoriatic Arthritis. 2025. https:\/\/doi.org\/10.1177\/24755303251318976.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"1483_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/1346-8138.15657","volume":"48","author":"K Hayama","year":"2021","unstructured":"Hayama K, Fujita H, Iwatsuki K, Terui T. Improved quality of life of patients with generalized pustular psoriasis in Japan: a cross-sectional survey. J Dermatol. 2021;48(2):203\u20136.","journal-title":"J Dermatol"},{"key":"1483_CR16","unstructured":"Lebwohl M, Eyerich K, Pink A, et al. Symptom and impact experience of adults with generalized pustular psoriasis (GPP) or palmoplantar pustulosis (PPP): an international web survey and qualitative interview study. Abstract #2324. Presented at: World Congress of Dermatology, 3\u20138 July 2023, Singapore."},{"issue":"11","key":"1483_CR17","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1016\/j.jid.2023.09.194","volume":"143","author":"D Jullien","year":"2023","unstructured":"Jullien D, Affandi AM, Jong TJ, et al. 186 Real-world clinical characteristics and treatment practices in generalized pustular psoriasis as seen in a chart review (SCRIPTOR). J Invest Dermatol. 2023;143(11):S363.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1483_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S0033291796004242","volume":"27","author":"DP Goldberg","year":"1997","unstructured":"Goldberg DP, Gater R, Sartorius N, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med. 1997;27(1):191\u20137.","journal-title":"Psychol Med"},{"key":"1483_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1477-7525-1-66","volume":"1","author":"A Montazeri","year":"2003","unstructured":"Montazeri A, Harirchi AM, Shariati M, Garmaroudi G, Ebadi M, Fateh A. The 12-item general health questionnaire (GHQ-12): translation and validation study of the Iranian version. Health Qual Life Outcomes. 2003;1:66.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1483_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s40359-024-01808-4","volume":"12","author":"A Comotti","year":"2024","unstructured":"Comotti A, Barnini T, Fattori A, et al. Rethinking students\u2019 mental health assessment through GHQ-12: evidence from the IRT approach. BMC Psychol. 2024;12(1):308.","journal-title":"BMC Psychol"},{"key":"1483_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u201321.","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"1483_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health. 2017;20(7):838\u201355.","journal-title":"Value Health"},{"issue":"1","key":"1483_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-023-01073-0","volume":"14","author":"A Balato","year":"2024","unstructured":"Balato A, Ambrogio F, Burlando M, et al. Commentary: unmet needs in generalized pustular psoriasis in clinical practice. Dermatol Ther (Heidelb). 2024;14(1):5\u201313.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 1","key":"1483_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40257-021-00664-x","volume":"23","author":"M Zheng","year":"2022","unstructured":"Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):5\u201312.","journal-title":"Am J Clin Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01483-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:14:07Z","timestamp":1758719647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01483-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01483-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lauren CS Kole has received consulting fees from Boehringer Ingelheim and participated in clinical trials for AbbVie and Ortho Dermatologics. Yayoi Tada has received honoraria and\/or grants from AbbVie, Boehringer Ingelheim, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB. Sascha Gerdes has acted as an advisor for, and\/or has received speakers\u2019 honoraria and\/or grants from, and\/or has participated in clinical trials for AbbVie, Adimune Inc, Affibody AB, Akari Therapeutics Plc, Almirall-Hermal, Amgen, Argenx BV, Aristea Therapeutics, Biogen Idec, Bioskin, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, Hexal AG, Incyte Inc., Janssen-Cilag, Johnson & Johnson, Klinge Pharma, Kymab, LEO Pharma, Medac, MSD, Neubourg Skin Care GmbH, Novartis, Pfizer, Pierre Fabre, Principia Biopharma, Regeneron Pharmaceutical, Sandoz Biopharmaceuticals, Sanofi-Aventis, Trevi Therapeutics, and UCB. Alice B Gottlieb has received research\/educational grants from Bristol Myers Squibb, Highlights Therapeutics, Janssen, and UCB Pharma (all paid to Mount Sinai School of Medicine until 2 May 2025); and received honoraria as an advisory board member and consultant from Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli Lilly, Highlights Therapeutics, Janssen, Novartis, Sanofi, Teva, UCB, and Xbiotech (stock options for Rheumatoid Arthritis). Matthias Augustin has acted as a consultant and\/or paid speaker, has received research grants and\/or honoraria for consulting and\/or scientific lectures, and\/or received travel expense reimbursement and\/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen-Cilag, LEO Pharma, MEDAC Pharma, Merck Sharp & Dohme, Mundipharma, Novartis, Pfizer, Pohl-Boskamp, Sandoz, and XenoPort. Min Zheng has participated in advisory boards and\/or acted as an investigator and\/or speaker for and received grants and\/or honoraria from AbbVie, Janssen-Cilag, Boehringer Ingelheim, LEO Pharma China, Xian-Janssen, Novartis, and Pfizer Inc. Hideaki Miyachi has received speaker\u2019s honoraria and\/or consultant fees from companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, and UCB. Iris Chen-Yin Lai is a co-investigator for several vaccine trials carried out at National Taiwan University Children\u2019s Hospital. S Ren\u00e9e Marshall, Smita Jha, and Ferhal K\u00fc\u00e7\u00fckosman are employees of Boehringer Ingelheim. Gang Wang has received honoraria and\/or grants from AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, and Novartis Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki of 1964 and its later amendments. Ethics committee approval was not required for this study. The research conducted (qualitative patient surveys and interviews) complied with local Data Protection Laws and the Market Research Society\u2019s Code of Conduct, including ESOMAR, EphMRA and all other relevant national codes of practice. All patients provided written informed consent for participation in the study and the use of their de-identified, anonymized, aggregated data for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}